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Greater body mass index is a better
predictor of subclinical cardiac damage at
long-term follow-up in men than is insulin
sensitivity: a prospective, population-based
cohort study
Mette Lundgren Nielsen1*, Manan Pareek1, Oke Gerke2, Margrét Leósdóttir3, Peter M. Nilsson4
and Michael Hecht Olsen1,5
Abstract
Background: To examine whether lower insulin sensitivity as determined by homeostatic model assessment (HOMA-%S)
was associated with increased left ventricular mass (LVM) and presence of LV diastolic dysfunction at long-term follow-up,
independently of body mass index (BMI), in middle-aged, otherwise healthy males.
Methods: Prospective population-based cohort study with a median (IQR) follow-up time of 28 (27–28) years, in which
traditional cardiovascular risk factors, including HOMA-%S and BMI, were assessed at baseline, and echocardiographic
determination of LVM and LV diastolic function was performed at follow-up. Associations between risk factors and
echocardiographic variables were tested using multivariable linear and binary logistic regression.
Results: The study population comprised 247 men with a median (IQR) age of 47 (47–48) years. Mean (SD) BMI was
25.1 +/− 3.0 kg/m2, and median (IQR) HOMA-%S was 113.0 (68.3–284.6). Subjects with low insulin sensitivity (lowest
HOMA-%S quartile (Q1)) had significantly greater BMI, fasting plasma insulin, and higher fasting blood glucose
(FBG) (p <0.02 for all). BMI and HOMA-%S were significantly correlated (r = −0.383, p <0.0001). At follow-up, mean
(SD) LVM and LVMI were 202 +/− 61 g and 103 +/− 31 g/m2, respectively, whereas median (IQR) E/é was 10 (8–12).
Moreover, 36 % had grade 2 or 3 diastolic dysfunction. In multivariable analyses, greater BMI, but not low insulin
sensitivity was independently associated with later detection of increased LVM and diastolic dysfunction.
Conclusion: Greater baseline BMI, but not lower insulin sensitivity was independently associated with greater
LVM and diastolic dysfunction at long-term follow-up.
Keywords: Diastolic dysfunction, Homeostatic model assessment, Insulin sensitivity, Body mass index, Left
ventricular mass, Prospective cohort study
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Background
Diastolic dysfunction of the left ventricle (LV) is character-
ized by delayed active relaxation and increased chamber
stiffness [1]. The condition is most commonly associated
with ischemic heart disease and/or hypertension with sub-
sequent concentric remodeling or hypertrophy of LV
(LVH) [2]. LV diastolic dysfunction and LVH are powerful
independent predictors of future cardiovascular mor-
bidity and mortality [3, 4], and identification of other
hemodynamic and non-hemodynamic factors associated
with the development of these often subclinical cardiac
conditions may unveil novel targets for prevention.
Both LV diastolic dysfunction and LVH are common
findings among patients with diabetes mellitus (DM) [5–7].
The associations are independent of concomitant hyper-
tension and ischemic heart disease, which has led to the
term diabetic cardiomyopathy, defined as ventricular dys-
function in a patient with DM, occurring independently of
an otherwise recognized cause [8]. However, the patho-
genic mechanisms for development of this condition are
poorly understood. Insulin resistance and the accom-
panying hyperinsulinemia may constitute an important
pathophysiological link in subjects with obesity, glucose
intolerance, or overt DM, but the majority of studies so
far have yielded inconsistent results, particularly due to
inadequate adjustment for key confounders, notably
body size, blood pressure, and glucose levels [9–11].
Additionally, most previous studies addressing this
subject have been of cross-sectional nature, which, be-
sides the inability to establish causality, are further lim-
ited by the fact that there is evidence to suggest that the
changes in LV structure and function may be conse-
quences of long-term, rather than short-term, metabolic
abnormalities [12].
Therefore, we conducted this study in subjects free from
DM and overt cardiovascular disease at baseline aiming to
examine whether lower insulin sensitivity as determined
by homeostatic model assessment (HOMA-%S) was asso-
ciated with increased left ventricular mass (LVM) and
presence of LV diastolic dysfunction at long-term follow-
up, independently of body mass index (BMI).
Methods
Study population
Study subjects were derived from the Malmö Preventive
Project (MPP, 1974–1992, n = 33,346), a population-
based cohort study aiming to screen for cardiovascular
risk factors, alcohol abuse, and breast cancer among in-
habitants in Malmö, Sweden, born between 1921 and
1949 [13]. All subjects answered a self-administered
questionnaire on lifestyle, medical history, and current
medication. Height and weight in light indoor clothing
were measured, and body mass index (BMI) was calcu-
lated. Blood pressure was measured twice after 10 min
of supine rest, with the mean value recorded for analysis.
Moreover, blood samples were obtained after an over-
night fast with measurement of blood glucose, plasma
insulin, serum lipids, and serum creatinine. In 18,960
participants without prevalent DM, a 120 min oral glucose
tolerance test (OGTT) was performed by a standard
method (30 g/m2 body surface area (BSA) in a 10 %
aqueous solution) [14]. A re-examination study (MPP-
RES, n = 18,238) was conducted between 2002 and
2006. In a subsample of 1,792 individuals therefrom, an
echocardiography and a 12-lead ECG recording were
carried out. These subjects were randomly selected
from groups defined by fasting plasma glucose (FPG),
with oversampling in groups of subjects with impaired
fasting glucose and DM, in order to ensure a sufficient
number of individuals in each category. MPP and MPP-
RES were approved by the Ethics Committee of Lund
University, Sweden and conducted in accordance with
the Declaration of Helsinki. Written informed consent
was obtained from all participants.
Final study population
Subjects with missing fasting blood glucose (FBG) and/or
fasting plasma insulin measurements at baseline (n =
26,057) were excluded from the present study. Remaining
subjects with prevalent cardiovascular disease (n = 33),
DM (n = 215), and/or other missing baseline variables
(n = 13), were likewise excluded. Of the 7032 subjects
left, 305 subjects had an echocardiography performed
at follow-up, with 263 subjects potentially eligible for
the current study (missing echocardiography variables,
n = 42). Since only 16 subjects were female, they were
excluded as well, leaving a final study population com-
prising 247 males (Fig. 1). Relevant definitions are pro-
vided below.
Investigations performed at baseline
Prevalent cardiovascular disease or diabetes mellitus
Prevalent cardiovascular disease was defined by the
International Classification of Diseases (ICD-9 and
ICD-10) codes gathered from the Swedish Hospital Dis-
charge Registry as well as local hospital and study regis-
tries and encompassed previous myocardial infarction,
transient ischemic attack, and stroke. Prevalent diabetes
mellitus was defined as self-reported diabetes mellitus
or according to the 1985 World Health Organization
(WHO) criteria for DM by either FBG or during 120 min
OGTT [15].
Insulin sensitivity (HOMA-%S)
HOMA-%S was derived via the computerized HOMA-
calculator (©The University of Oxford 2004) using FBG
and fasting plasma insulin (measured by standard radio-
immunoassay) as input [16]. Based on sensitivity analyses
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regarding LV diastolic dysfunction, low insulin sensitivity
was defined as the lowest HOMA-%S quartile (Q1),
whereas quartiles 2–4 (Q2-4) were defined as normal in-
sulin sensitivity.
Investigations performed at follow-up
Echocardiography
Echocardiography was conducted with a 3V2c trans-
ducer (Acuson Sequoia, Mountain View, CA) or an S3
transducer (Sonos 5500 Philips, Andover, MA). LV ejec-
tion fraction (LVEF) was quantified visually. LVM calcula-
tions were based on 2-dimensional linear measurements
in the parasternal long-axis view at the tips of the mitral
valve leaflets at end-diastole, perpendicular to the long
axis of LV. The thickness of the interventricular septum
(IVS), LV internal diameter (LVID), and the thickness of
the posterior wall (PW) were obtained by placing the cali-
pers on the interface between myocardial wall and cavity
and the interface between myocardial wall and pericar-
dium, respectively. LVM was then calculated using the
Cube formula recommended by the American Society of
Echocardiography (ASE) and the European Association of
Cardiovascular Imaging (EACVI), and indexed for BSA,
obtaining LVMI [17]. LV diastolic function was assessed in
the apical four-chamber view using transmitral pulsed
Doppler flow with a 1–3 mm sample volume placed
between the tips of the mitral valve leaflets (obtaining
E, A, and E-wave deceleration time (DT)) and tissue
Doppler imaging with the sample volume positioned
within 1 cm of the septal and lateral borders of the mi-
tral annulus (obtaining both septal and lateral é and
averaging the values for the analyses). A mean of 3–5
cycles was used. The intra- and interobserver variabil-
ities are reported elsewhere [18]. Diastolic function
was graded according to the recommendations of
American Society of Echocardiography and European
Association of Cardiovascular Imaging [19], using age-
appropriate cut-off values of septal é, lateral é, E-wave
DT, E/A, and averaged E/é. If septal é was ≥8 and/or
lateral é was ≥10, subjects were classified as having
normal diastolic function. If septal é was <8 and lateral
é was <10, subjects were classified as having diastolic
dysfunction, and the values of E-wave DT, E/A, and E/é
were used for grading subjects into grade 1, 2 or 3 dia-
stolic dysfunction, as previously described (Table 1)
[20]. Equivocal cases, i.e. subjects who were in a
Fig. 1 Flowchart showing the study population selection









Septal é (cm/s) ≥8 <8 <8 <8
Lateral é (cm/s) ≥10 <10 <10 <10
E-wave DT (ms) 140–240 ≥240 140–240 <140
E/A 0.8–1.5 <0.8 0.8–1.5 >1.5
E/é <9 ≤12 ≥9 ≥13
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transitional state between grade 1 and 2 diastolic dys-
function with E/é ≥9 and ≤12, but E/A and E-wave DT
pointing in opposite directions, were classified as un-
determined diastolic dysfunction. If E/é was >12, subjects
were classified as having either grade 2 or 3 diastolic
dysfunction. Finally, all subjects with E/é <9 were
classified as either normal (E-wave DT <240 ms and
E/A ≥0.8) or grade 1 diastolic dysfunction (all other
subjects), even if they did not strictly fulfill the pri-
mary é criteria for normal diastolic function. Grade 2
and 3 diastolic dysfunction were grouped together,
since only two individuals fulfilled the criteria for
grade 3 diastolic dysfunction.
Statistical analysis
Continuous variables were summarized by means and
standard deviations (approximately normally distributed
variables) and medians and interquartile ranges (IQR)
(non-normally distributed variables), whereas categorical
variables were presented by frequencies and corresponding
percentages. Group-wise comparisons were performed
using independent samples t-test, Mann-Whitney U-test,
and Pearson’s χ2-test or Fisher’s exact test (depending on
cell frequencies), respectively. The associations between
risk factors and LVM, LVMI, or E/é, respectively, were
assessed by multivariable linear regression. Since E/é was
moderately positively skewed, the association between E/é
and various risk factors was assessed by linear regression
after natural log-transformation of E/é. The association
between risk factors and diastolic function, i.e. normal
or grade 1 diastolic dysfunction vs. grade 2 or 3 dia-
stolic dysfunction, was assessed by binary logistic re-
gression. Statistically and clinically significant variables
were included in the final multivariable linear and binary
logistic regression models, and stepwise subset selection
was applied for adjustment of these models with a p-stay
of 0.2. The significance level for the univariable analyses
was 5 %. In all cases, time elapsed from baseline inclusion
to echocardiography at follow-up was included as an
explanatory variable under the assumption that it
could impact the severity of the echocardiographic
findings. All analyses were carried out using IBM
SPSS Statistics 22 (IBM, Armonk, New York, USA) and
Stata/IC 13 (StataCorp LP, College Station, Texas, USA).
Results
Characteristics of the study population
After applying the aforementioned exclusion criteria, a
study cohort of 247 subjects was left for analysis. At
baseline, subjects were middle-aged with a median age
of 47 (IQR 47–48) years, mean systolic blood pressure
129 +/− 15 mmHg, and borderline overweight with
mean BMI 25.1 +/− 3.0 kg/m2. Total cholesterol was
mildly elevated at 5.7 +/− 1.0 mmol/L. Median HOMA-
%S was 113.0 (IQR 68.3–284.6). Subjects with low insu-
lin sensitivity (HOMA-%S Q1) had significantly greater
BMI, fasting plasma insulin and both higher FBG and
BG at 120 min, borderline significantly greater systolic
blood pressure, but there were no significant between-
group differences regarding age, smoking status, and
total cholesterol. BMI and HOMA-%S were significantly
correlated (Pearson’s r = −0.383, p <0.0001). At follow-
up, mean LVMI was 103 +/− 31 g/m2, and median E/é
was 10 (IQR 8–12). Moreover, 36 % (when excluding
the 20 subjects with undetermined diastolic dysfunc-
tion) had grade 2 or 3 diastolic dysfunction. Subjects
with low insulin sensitivity had a borderline significantly
greater prevalence of grade 2 or 3 diastolic dysfunction,
whereas there was no significant between-group differ-
ence with respect to LVEF. Tables 2 and 3 show the
baseline characteristics of the subjects categorized ac-
cording to HOMA-%S category and diastolic function,
respectively. Furthermore, Additional file 1: Table S1
shows the baseline characteristics according to BMI cat-
egory, i.e. non-overweight vs. overweight or obese subjects.
Left ventricular size
There were no significant differences in neither LVM
(205 +/− 61 g/m2 vs. 201 +/− 61 g/m2, p = 0.7) nor
LVMI (103 +/− 30 g/m2 vs. 103 +/− 30 g/m2, p = 0.9)
between subjects with low vs. normal insulin sensitivity
according to HOMA-%S. In univariable analyses, higher
values of both LVM and LVMI were significantly associ-
ated with higher BMI, but not HOMA-%S category. The
adjusted multivariable linear regression models are pre-
sented in Tables 4 and 5 and included only BMI,
whereas age and HOMA-%S category were forced into
the models. Smoking status, systolic blood pressure, total
cholesterol, fasting plasma insulin, creatinine, and seden-
tary lifestyle were not significantly associated with LVM
or LVMI on univariable analyses and therefore not in-
cluded in the final multivariable regression models. We
did not detect any significant interactions regarding
HOMA-%S. Furthermore, the results were not affected
by BMI alterations during follow-up, i.e. whether the
individuals gained or lost weight, even when stratified
for whether or not they where initially overweight
(results not shown, available upon request).
Diastolic function
There was no significant difference in E/é according to
HOMA-%S category (Q1: median 10 (IQR: 8–12) vs. Q2-
4 median: 10 (IQR: 7–12), p = 0.2)), whereas grade 2 or 3
diastolic dysfunction was borderline significantly more
prevalent among subjects with low vs. normal HOMA-%S
(47 % vs. 33 %, p = 0.06). In univariable analyses, higher E/
é was associated with higher age, BMI, serum creatinine,
and shorter follow-up time, while diastolic dysfunction
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was associated with higher BMI and shorter follow-up
time, but not serum creatinine. The adjusted multivariable
regression models are shown in Tables 6 and 7. In both
cases, HOMA-%S was forced into the models. Smoking
status, systolic blood pressure, total cholesterol, fasting
plasma insulin, and sedentary lifestyle were not significantly
associated with E/é or the presence of diastolic dysfunction
on univariable analyses and therefore not included in the
multivariable regression models. No significant interactions
were detected with respect to HOMA-%S. Regarding BMI
changes, the same was true as for LV size (results not
shown, available upon request).
Discussion
In this prospective population-based cohort study com-
prising middle-aged male, apparently healthy subjects,
we found that greater BMI, but not lower insulin sensi-
tivity defined as the lowest HOMA-%S quartile was
associated with later detection of increased LVM and
grade 2 or 3 LV diastolic dysfunction. Low insulin sensi-
tivity (HOMA-%S Q1) was only associated later recogni-
tion of grade 2 or 3 LV diastolic dysfunction in
univariable analysis, but the association was lost after
adjusting for BMI. As expected, BMI and HOMA-%S
were significantly correlated.
Conflicting results have been reported regarding the
relationship between insulin sensitivity and both indexed
and non-indexed LVM, and to our knowledge, none of
these were prospective. In a small study comprising 29
non-obese, glucose-tolerant subjects with borderline
hypertension, Phillips et al. found a significant independ-
ent association between LVMI and insulin sensitivity







P-value for difference between
HOMA-S categories
Baseline MPP
Age (years) 47 [47–48] 47 [47–48] 47 [47–48] 0.1c
Active smoking 118 (48 %) 27 (43 %) 91 (50 %) 0.4a
BMI (kg/m2) 25.1 +/− 3.0 26.9 +/− 3.8 24.5 +/− 2.4 <0.0001b
Systolic blood pressure (mmHg) 129 +/− 15 133 +/− 19 128 +/− 14 0.0502b
Total cholesterol (mmol/L) 5.7 +/− 1.0 5.9 +/− 1.3 5.7 +/− 0.9 0.2b
Creatinine (μmol/L) 93 +/− 13 93 +/− 13 92 +/− 13 0.7b
FBG (mmol/L) 5.1 +/− 0.5 5.2 +/− 0.6 5.0 +/− 0.5 0.02b
Fasting insulin (pmol/L) 48 [18–78] 108 [90–144] 36 [18–54] <0.0001c
HOMA-%B 83.2 [54.4–124.2] 147.2 [118.8–184.4] 67.3 [47.8–92.1] <0.0001c
HOMA-%S 113.0 [68.3–284.6] 50.2 [37.1–61.9] 150.7 [99.3–289.7] <0.0001c
Sedentary lifestyle 143 (58 %) 38 (60 %) 105 (57 %) 0.7a
Antihypertensive medication 11 (5 %) 4 (6 %) 7 (4 %) 0.4a
MPP re-examination
Age (years) 74 [70–75] 74 [70–75] 74 [71–75] 0.5c
Active smoking 33 (13 %) 8 (13 %) 25 (14 %) 0.9a
BMI (kg/m2) 27.9 +/− 3.6 28.3 +/− 4.3 27.8 +/− 3.3 0.3b
Systolic blood pressure (mmHg) 149 +/− 21 146 +/− 18 149 +/− 21 0.3b
Total cholesterol (mmol/L) 5.1 +/− 1.1 4.7 +/− 1.0 5.2 +/− 1.1 0.001b
FPG (mmol/L) 7.1 +/− 2.1 7.4 +/− 2.0 7.0 +/− 2.1 0.1b
LVM (g) 202 +/− 61 205 +/− 61 201 +/− 61 0.7b
LVMI (g/m2) 103 +/− 30 103 +/− 30 103 +/− 30 0.9b
EF (%) 60 +/− 8 60 +/− 8 60 +/− 8 0.5b
Grade 2 or 3 diastolic dysfunction 82 (36 %) 27 (47 %) 55 (33 %) 0.06a
E/é 10 [8–12] 10 [8–12] 10 [7–12] 0.3c
Time (years) 28 [27–28] 28 [25–29] 28 [27–28] 0.4c
Categorical variables (active smoking, grade 2 or 3 diastolic dysfunction) are given as n (%), whereas continuous variables are given as mean +/− SD
(approximately normally distributed variables, i.e. body mass index (BMI), systolic blood pressure, total cholesterol, creatinine, fasting blood glucose (FBG), fasting
plasma glucose (FPG), left ventricular mass (LVM), left ventricular mass index (LVMI), ejection fraction (EF)) or median (IQR) (non-normally distributed variables, i.e.
age, fasting insulin, HOMA-%S, HOMA-%B, E/é, and time)
aPearson’s χ2-test; bindependent samples t-test; cMann-Whitney U test
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[21]. Subjects were age-wise comparable to our cohort;
however, insulin sensitivity was derived by frequent sam-
pling during OGTT. Likewise, Sundström et al. [22]
found a borderline significant association between insu-
lin resistance according to HOMA (HOMA-IR) and
LVMI in normotensive subjects, but they did not adjust
for glucometabolic status. On the contrary, in one of the
largest studies to date, based on the Framingham Heart
Study [10] cohort, HOMA-IR was associated with in-
creased LVM among women only, although the relation-
ship was largely accounted for by obesity. Further
supporting our results, neither Galvan et al. [11] nor
Ebinc et al. [23] were able to detect an association
between LVM and insulin resistance, independently of
BMI, in subjects without DM. Although a number of
other studies exist, direct comparison is challenging, es-
pecially due to limited sample sizes and heterogeneous
study populations, with the majority having assessed
subjects already at increased cardiovascular risk, i.e. sub-
jects who were obese, had DM, or were hypertensive.
Such individuals have greater insulin resistance and
LVM than the general population [24, 25], providing
limited pathophysiological understanding regarding sub-
jects in whom non-hemodynamic LVH-inducing mecha-
nisms are likely to be more important. Adjustment for
these important confounders has also been quite variable
[11]; for instance, some of the described relations of in-
sulin resistance to LVM may have been mainly due to
the effects of blood pressure. A true association between
insulin LV size and function is therefore more likely be
revealed in a general population-based study.
Asymptomatic LV diastolic dysfunction is the most
prominent characteristic of diabetic cardiomyopathy
[8, 26]. However, since LV diastolic function may
Table 3 Baseline characteristics according to diastolic function. Similar variables, obtained at follow-up, are depicted for comparison
Variable All subjects
(n = 227)
Normal or grade 1 diastolic
dysfunction (n = 145)
Grade 2 or 3 diastolic
dysfunction (n = 82)
P-value for difference between
diastolic dysfunction categories
MPP baseline
Age (years) 47 [47–48] 47 [47–48] 47 [47–48] 0.5c
Active smoking 109 (48 %) 73 (50 %) 36 (44 %) 0.4a
BMI (kg/m2) 25.1 +/− 3.1 24.7 +/− 3.0 25.9 +/− 3.1 0.003b
Systolic blood pressure (mmHg) 129 +/− 15 129 +/− 16 129 +/− 15 0.7b
Total cholesterol (mmol/L) 5.7 +/− 1.0 5.7 +/− 0.9 5.7 +/− 1.2 0.8b
Creatinine (μmol/L) 92 +/− 13 91 +/− 12 94 +/− 14 0.09b
FBG (mmol/L) 5.1 +/− 0.5 5.1 +/− 0.5 5.1 +/− 0.5 0.6b
Fasting insulin (pmol/L) 48 [38–84] 42 [18–72] 54 [18–84] 0.1c
HOMA-%B 100.3 [68.7–137.9] 77.7 [52.0–117.6] 92.5 [58.0–133.6] 0.2c
HOMA-%S 111.0 [64.1–138.4] 124.4 [75.9–286.5] 99.6 [62.8–279.7] 0.1c
Sedentary lifestyle 133 (59 %) 86 (59 %) 47 (57 %) 0.8a
Antihypertensive medication 10 (4 %) 6 (4 %) 4 (5 %) 0.8a
MPP re-examination
Age (years) 74 [70–75] 74 [71–75] 74 [70–75] 0.5c
Active smoking 32 (14 %) 22 (15 %) 10 (12 %) 0.5a
BMI (kg/m2) 27.9 +/− 3.5 27.4 +/− 3.3 28.9 +/− 3.7 0.002b
Systolic blood pressure (mmHg) 148 +/− 20 147 +/− 20 151 +/− 21 0.2b
Total cholesterol (mmol/L) 5.1 +/− 1.1 5.1 +/− 1.1 4.9 +/− 1.0 0.2b
FPG (mmol/L) 7.1 +/− 2.1 7.0 +/− 2.0 7.2 +/− 2.2 0.5b
LVM (g) 202 +/− 63 197 +/− 64 212 +/− 58 0.1b
LVMI (g/m2) 103 +/− 31 101 +/− 32 106 +/− 28 0.2b
EF (%) 60 +/− 9 60 +/− 8 62 +/− 10 0.09b
E/é 10 [7–12] 8 [7–10] 13 [12–15] <0.0001c
Time (years) 28 [28–29] 28 [27–29] 28 [25–28] 0.02c
Categorical variables (active smoking) are given as n (%), whereas continuous variables are given as mean +/− SD (approximately normally distributed variables,
i.e. body mass index (BMI), systolic blood pressure, total cholesterol, creatinine, fasting blood glucose (FBG), fasting plasma glucose (FPG), left ventricular mass
(LVM), left ventricular mass index (LVMI), ejection fraction (EF)) or median (IQR) (non-normally distributed variables, i.e. age, insulin, HOMA-%S, HOMA-%B, E/é,
and time)
aPearson’s χ2-test; bindependent samples t-test; cMann-Whitney U test
Nielsen et al. BMC Cardiovascular Disorders  (2015) 15:168 Page 6 of 10
already be impaired in the pre-diabetic or even preclin-
ical phase of glucometabolic disturbances, i.e. before
the onset of sustained hyperglycemia, an independent
mechanistic role of insulin resistance may exist [27–29].
Furthermore, LV diastolic dysfunction may be evident at
less severe insulin resistance when compared to the values
associated with measureable LV structural changes [30]. In
a population-based study including 1063 subjects, Fontes-
Carvalho et al. found a significant association between
higher insulin resistance according to HOMA-IR and
worse LV diastolic function, including lower lateral é vel-
ocity and higher E/é ratio [31]; however, without adjusting
for systolic blood pressure and BMI. Further supporting
these results, both Dinh et al. [32] and Hwang et al. [30]
found an independent association between insulin resist-
ance and both presence and severity of LV diastolic dys-
function, independently of overt DM; however, neither
studies adjusted for body size. In addition, all the above
mentioned studies were cross-sectional. In the present
study, we showed that BMI itself, but not insulin sensi-
tivity, was significantly associated with E/é and grade 2
or 3 diastolic dysfunction, in multivariable analysis. Never-
theless, direct comparison between different studies is
complicated by use of variable methods for assessment of
both LV diastolic function and insulin sensitivity as well as
inadequate adjustment for relevant confounders.
The highly prevalent co-existence of insulin resistance,
hyperinsulinemia, obesity, hypertension, and DM makes
it difficult to dissect the separate role of each of these
conditions for development of subclinical cardiac dam-
age [11]. However, at present time, there is insufficient
convincing evidence to conclude that LVM and preva-
lence of LV diastolic dysfunction are greater among sub-
jects with low insulin sensitivity or insulin resistance,
when adequate care is taken to adjust for DM, blood
pressure, and body size. Therefore, uncertainty remains,
as to why subjects with increased body size have greater
LV size and worse diastolic function [33–35]. Several
other risk factors, e.g. elevated blood pressure, glucose
and cholesterol levels, are associated with obesity, and
the progressive addition of metabolic risk factors seems
to be associated with greater LVM [36]. Just as proposed
for diabetic cardiomyopathy, the myocardial alterations
associated with obesity are likely to be a result of several
similar synergistically acting mechanisms [8], and it is
possible that low insulin sensitivity, as previously sug-
gested for fasting plasma glucose [20], primarily acts as an
effect modifier of these other risk factors. This hypothesis
is supported by the fact that most studies reporting a posi-
tive association between insulin resistance and subclinical
cardiac damage have involved subjects with other risk fac-
tors as well, and our chances of finding positive associa-
tions were weakened by the strict selection criteria
employed, aiming to exclude subjects with prevalent DM
or cardiovascular disease. Although we were not directly
able to find synergistic interactions between insulin sensi-
tivity and the traditional risk factors in the present study,
this could have resulted from the relatively small sample
size. The exact reason why baseline BMI, but not insulin
sensitivity, was associated with later cardiac damage in
our study, is uncertain. However, HOMA-indices display
pronounced biological variation, which decreases the
chances of finding such significant associations. Further-
more, the HOMA-indices show considerable temporal
changes, which may further reduce the predictive value at
long-term follow-up. Although BMI changes over time as
well, the fluctuations may more often be unidirectional
[37, 38].
Regardless of whether or not insulin resistance is the
main mediator of subclinical cardiac damage in obesity,
pre-diabetes, and DM, the strong association between
higher baseline BMI and later detection of structural
Table 6 Multivariable linear regression model for the prediction
of log(E/é) at follow-up (adjusted r2 = 0.152)
Risk factor β-coefficient (95 % CI) P-value
Age (per year) 0.02 (0.006 to 0.027) 0.003
BMI (per kg/m2) 0.03 (0.02 to 0.04) <0.0001
Creatinine 0.002 (−0.001 to 0.005) 0.18
Time (per year) −0.03 (−0.06 to −0.01) 0.01
HOMA-%S Q1 vs. Q2-4 −0.04 (−0.13 to 0.06) 0.5
Table 7 Binary logistic regression model for the prediction
of grade 2 or 3 diastolic dysfunction at follow-up (Nagelkerke
r2 = 0.078)
Risk factor Odds ratio (95 % CI) P-value
Age (per year) 1.03 (0.94 to 1.13) 0.5
BMI (per kg/m2) 1.12 (1.01 to 1.24) 0.03
Time (per year) 0.86 (0.73 to 1.02) 0.07
HOMA-%S Q1 vs. Q2-4 1.30 (0.66 to 2.56) 0.4
Table 4 Multivariable linear regression model for the prediction
of LVM at follow-up (adjusted r2 = 0.088)
Risk factor β-coefficient (95 % CI) P-value
Age (per year) 0.10 (−1.84 to 2.05) 0.9
BMI (per kg/m2) 6.69 (4.05 to 9.33) <0.0001
HOMA-%S Q1 vs. Q2-4 −12.46 (−30.19 to 5.27) 0.17
Table 5 Multivariable linear regression model for the prediction
of LVMI at follow-up (adjusted r2 = 0.040)
Risk factor β-coefficient (95 % CI) P-value
Age (per year) 0.37 (−0.61 to 1.36) 0.5
BMI (per kg/m2) 2.24 (0.91 to 3.58) 0.001
HOMA-%S Q1 vs. Q2-4 −5.18 (−14.17 to 3.799) 0.3
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and functional LV changes in our study suggests that
early weight loss in overweight or obese subjects may
halt the progression of adverse cardiac alterations, spe-
cifically reduce the risk of LVH and diastolic dysfunc-
tion. This is supported by the results from the Coronary
Artery Risk Development in Young Adults study, in
which increasing BMI over a 5- to 10-year follow-up in
generally healthy adults was associated with increasing
LVM [33, 34]. Further supporting this early preventive
strategy is the weak ability of therapeutic interventions,
e.g. intensive glycemic control [39, 40] and antihyperten-
sive drugs [41, 42], to lower cardiovascular risk, when
DM is overt, because the myocardial damage may have
become partly to completely irreversible at this point.
Lastly, early weight loss is associated with other clinically
relevant benefits, including a lower risk of hypertension,
dyslipidemia, and DM itself, which may further reduce
the risk of cardiovascular complications [43]. The lack of
our detection of a beneficial effect of BMI reduction in
the present study was most likely related to the small
number (n = 32) of subjects who actually lost weight
during the study period and the possible BMI fluctua-
tions over time that we were unable to account for. Even
in those having lost weight, the loss was very subtle in
most subjects. In addition, most individuals were
normo- or overweight, but not obese, making detection
of substantial benefits difficult.
Limitations
Although the participation rates of 71 % in MPP and
72 % in MPP-RES, respectively, are considered high, one
may still argue that the study subjects did not represent
a truly random population sample since people who
agree to take part may be healthier than the general
population. All subjects in the present study were male,
limiting the applicability of the results in females. More-
over, our exclusion of a vast amount of the original study
population in order to get a cohort of apparently healthy
subjects, who were alive and underwent echocardiog-
raphy, however with variable follow-up periods, may
introduce further selection bias, including survival bias,
and lack of adequate power.
Insulin sensitivity was not assessed according to the
gold standard method, i.e. the hyperinsulinemic euglyce-
mic clamp technique [44]. However, the use of fasting BG
and insulin was justified by the fact that HOMA-derived
parameters are strongly related to clamp-measured insulin
sensitivity and insulin resistance in subjects both with and
without DM [27, 45]. Sensitivity analyses with respect to
the prediction of LV size and LV diastolic dysfunction
were performed, before settling on the use of Q1 as
cut-off in the present study. Moreover, data on glucose
tolerance would have been desirable; however, in the
present study, inclusion of these data would have re-
duced sample size even further.
Similarly, the use of BMI as a surrogate marker for
obesity has some limitations [46–48], and the inclusion
of other measures, e.g. waist circumference and waist-
to-hip ratio would have been preferred; however, these
measurements were not available. The accuracy of BMI
for diagnosing obesity is especially limited for individuals
with BMI between 25.0 and 29.9 kg/m2, in men and in
the elderly. However, BMI or plain body weight may still
be the best way to evaluate changes in body fat content
over time, because increments in body weight or BMI
most likely represent fat gain [49].
Linear LV measurements have prognostic value and
are feasible, especially when studying large populations.
However, the method is based solely on basal dimen-
sions, unable to accommodate for LV shape and size
changes that might occur along the long axis of the
chamber, and the formula for calculating LVM assumes
normal LV geometry and cubes the linear measurements.
Therefore, even small errors may significantly influence
the calculated mass [17]. Although echocardiography
does not directly measure the same parameters for dia-
stolic function that are measured invasively, it is still the
most practical and recommended routine clinical ap-
proach. However, some limitations deserve mentioning.
Minimal angulation is essential for reliable spectral Doppler
measurements. Additionally, the usefulness of é velocity in
normal subjects may be limited, as preload increases é in
these subjects. The correlation between E/é between 8
and 15 using septal é (9–13 in the present study) and
mean LV diastolic pressure displays wide variability
[50]. Therefore, although increased E/é is indicative of
an elevated LV filling pressure, it should not be used as
stand-alone parameter when drawing conclusions about
LV diastolic dysfunction. Furthermore, our grading of
LV diastolic dysfunction could have been more robust,
had we also been able to incorporate the left atrial volume
index [19]. Lastly, the lack of an echocardiography at base-
line prevented us from directly assessing LV structural and
functional changes over time.
Conclusion
In conclusion, in a prospective population-based cohort
study including apparently healthy middle-aged male sub-
jects, greater baseline BMI, but not lower insulin sensitivity
was independently associated with greater LVM and dia-
stolic dysfunction at long-term follow-up.
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